Ballentine Partners Has Upped Its Bristol Myers Squibb Co (BMY) Holding; Actuant (ATU) Covered By 2 Bulls

Actuant Corporation (NYSE:ATU) Logo

Among 5 analysts covering Actuant (NYSE:ATU), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. Actuant had 7 analyst reports since September 27, 2018 according to SRatingsIntel. Wells Fargo maintained the shares of ATU in report on Friday, October 19 with “Market Perform” rating. The firm has “Neutral” rating given on Monday, January 28 by JP Morgan. The company was maintained on Friday, December 21 by Robert W. Baird. BMO Capital Markets maintained the shares of ATU in report on Thursday, September 27 with “Market Perform” rating. The company was maintained on Friday, December 21 by Wells Fargo. KeyBanc Capital Markets maintained the stock with “Overweight” rating in Friday, December 21 report. See Actuant Corporation (NYSE:ATU) latest ratings:

26/02/2019 Broker: BidaskScore Rating: Buy Upgrade
28/01/2019 Broker: JP Morgan Old Rating: Underweight New Rating: Neutral Old Target: $19 New Target: $23 Upgrade
21/12/2018 Broker: Wells Fargo Old Rating: Market Perform New Rating: Market Perform Old Target: $27 New Target: $21 Maintain
21/12/2018 Broker: Robert W. Baird Old Rating: Outperform New Rating: Outperform Old Target: $32 New Target: $26 Maintain
21/12/2018 Broker: KeyBanc Capital Markets Old Rating: Overweight New Rating: Overweight Old Target: $32 New Target: $27 Maintain
19/10/2018 Broker: Wells Fargo Old Rating: Market Perform New Rating: Market Perform Old Target: $29 New Target: $27 Maintain
27/09/2018 Broker: BMO Capital Markets Old Rating: Market Perform New Rating: Market Perform Old Target: $27 New Target: $26 Maintain

Ballentine Partners Llc increased Bristol Myers Squibb Co (BMY) stake by 154.37% reported in 2018Q4 SEC filing. Ballentine Partners Llc acquired 18,714 shares as Bristol Myers Squibb Co (BMY)’s stock rose 2.02%. The Ballentine Partners Llc holds 30,837 shares with $1.60M value, up from 12,123 last quarter. Bristol Myers Squibb Co now has $81.57 billion valuation. The stock increased 0.14% or $0.07 during the last trading session, reaching $49.96. About 27.37 million shares traded or 46.14% up from the average. Bristol-Myers Squibb Company (NYSE:BMY) has declined 19.24% since March 17, 2018 and is downtrending. It has underperformed by 23.61% the S&P500. Some Historical BMY News: 13/04/2018 – Opdivo (nivolumab), First PD-1 Inhibitor to Demonstrate Superior Survival Benefit Compared with Chemotherapy in a Predominantly; 03/05/2018 – BRISTOL-MYERS – PROPOSAL ON DISCLOSING RISKS RELATED TO CONCERN OVER DRUG PRICING STRATEGIES INCORPORATED INTO INCENTIVE COMPENSATION PLANS WAS NOT APPROVED; 15/03/2018 – Exelixis Submits U.S. Supplemental New Drug Application for CABOMETYX® (Cabozantinib) for Previously Treated Advanced; 23/03/2018 – MERCY INVESTMENT SERVICES SAYS URGES BRISTOL MYERS SHAREHOLDERS TO VOTE FOR PROPOSAL #4 – SEC FILING; 23/05/2018 – MERCK & CO – SUBMITTED SBLA FOR KEYTRUDA IN COMBINATION TO U.S. FDA AND NEW DATA WILL BE SHARED WITH AGENCY; 19/03/2018 – Rhode Island DoA: Bristol Warren Regional School District Mon, 3/19/2018, 7:00 PM; 16/04/2018 – AstraZeneca Presents Imfinzi (durvalumab) Plus tremelimumab Combination Data at AACR Annual Meeting; 27/03/2018 – Bristol-Myers: FDA Grants Combination Breakthrough Therapy Designation for Potential Indication; 07/05/2018 – FDA GRANTS PRIORITY REVIEW TO GENENTECH’S TECENTRIQ; 29/05/2018 – Roche: Study is on Tecentriq Plus Chemotherapy for Type of Lung Cancer

More notable recent Bristol-Myers Squibb Company (NYSE:BMY) news were published by: Seekingalpha.com which released: “Starboard gauges support for BMY-CELG deal – Seeking Alpha” on February 17, 2019, also Streetinsider.com with their article: “Bristol-Myers (BMY) Had Informal, High Level Past Deal Talks with Others; Past Talks Had no Terms, were Informal, no Offers – Bloomberg, Citing CEO – StreetInsider.com” published on March 12, 2019, Seekingalpha.com published: “Idera completes enrollment in tilsotolimod expansion study – Seeking Alpha” on February 27, 2019. More interesting news about Bristol-Myers Squibb Company (NYSE:BMY) were released by: Investorplace.com and their article: “Friday’s Vital Data: Bristol-Myers Squibb, Intel and Activision Blizzard – Investorplace.com” published on February 15, 2019 as well as Streetinsider.com‘s news article titled: “Bristol-Myers Squibb (BMY) call put ratio 1 call to 1.1 put into Wellington says it does not support Bristol-Myers’ acquisition of Celgene – StreetInsider.com” with publication date: February 28, 2019.

Ballentine Partners Llc decreased Forrester Resh Inc (NASDAQ:FORR) stake by 296,229 shares to 250,000 valued at $11.18 million in 2018Q4. It also reduced Ishares Tr (ICF) stake by 5,480 shares and now owns 117,792 shares. Spdr Index Shs Fds (EWX) was reduced too.

Investors sentiment decreased to 0.78 in 2018 Q4. Its down 0.10, from 0.88 in 2018Q3. It worsened, as 89 investors sold BMY shares while 550 reduced holdings. 126 funds opened positions while 371 raised stakes. 1.16 billion shares or 2.02% more from 1.14 billion shares in 2018Q3 were reported. Northrock Ptnrs Lc stated it has 4,480 shares or 0.07% of all its holdings. Alpha Cubed Invs Limited Liability stated it has 0.05% in Bristol-Myers Squibb Company (NYSE:BMY). North Star Management holds 0.26% or 38,503 shares. Vident Inv Advisory Limited Liability Company reported 0.18% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY). Mirador Prtn Lp reported 35,308 shares or 1.13% of all its holdings. Rockland Tru holds 0.51% or 79,347 shares. Moreover, Live Your Vision has 0.03% invested in Bristol-Myers Squibb Company (NYSE:BMY). Inv Of Virginia Limited Liability Com holds 47,313 shares or 0.64% of its portfolio. 870 are owned by Grisanti Management Lc. Sunbelt invested 0.17% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY). Moreover, National Bank Of Stockton has 0.44% invested in Bristol-Myers Squibb Company (NYSE:BMY) for 13,885 shares. Lourd Limited Com owns 33,129 shares. Charter Trust Company reported 38,176 shares. Folger Nolan Fleming Douglas Management stated it has 833 shares. Curbstone Management Corp holds 0.18% or 11,814 shares in its portfolio.

Among 9 analysts covering Bristol-Myers Squibb (NYSE:BMY), 4 have Buy rating, 0 Sell and 5 Hold. Therefore 44% are positive. Bristol-Myers Squibb had 14 analyst reports since October 8, 2018 according to SRatingsIntel. As per Tuesday, February 19, the company rating was maintained by Bank of America. The firm has “Outperform” rating given on Thursday, December 6 by BMO Capital Markets. The company was maintained on Friday, October 12 by Barclays Capital. The stock has “Market Perform” rating by BMO Capital Markets on Tuesday, October 23. BMO Capital Markets maintained it with “Buy” rating and $59 target in Thursday, February 28 report. BMO Capital Markets maintained Bristol-Myers Squibb Company (NYSE:BMY) on Friday, November 16 with “Market Perform” rating. The firm has “Neutral” rating given on Monday, October 22 by Citigroup. JP Morgan maintained Bristol-Myers Squibb Company (NYSE:BMY) on Monday, October 8 with “Overweight” rating. The firm has “Hold” rating by Guggenheim given on Tuesday, November 27. The firm has “Equal-Weight” rating given on Tuesday, November 6 by Morgan Stanley.

The stock increased 2.02% or $0.49 during the last trading session, reaching $24.79. About 643,859 shares traded or 93.80% up from the average. Actuant Corporation (NYSE:ATU) has risen 10.98% since March 17, 2018 and is uptrending. It has outperformed by 6.61% the S&P500. Some Historical ATU News: 21/03/2018 – ACTUANT CORP ATU.N SEES FY ADJUSTED SHR $1.00 TO $1.10; 21/03/2018 – ACTUANT 2Q ADJ EPS 13C, EST. 15C; 21/03/2018 – CORRECT: ACTUANT SEES FY ADJ EPS $1.00 TO $1.10, EST. $1.05; 21/03/2018 – ACTUANT CORP ATU.N FY SHR VIEW $1.05, REV VIEW $1.13 BLN — THOMSON REUTERS l/B/E/S; 25/04/2018 – Actuant Closes Below 50-Day Moving Average: Technicals; 21/03/2018 – Actuant Raises 2018 View To Rev $1.14B-$1.16B; 07/05/2018 – Actuant Announces General Counsel Appointment; 21/03/2018 – Actuant Adjusts Fiscal 2018 Guidance; 30/03/2018 – S&P REVISES ACTUANT CORP. TO RATING ‘BB’ FROM ‘BB+’; OUTLOOK ‘NEGATIVE’; 21/03/2018 – Actuant Sees 3Q Rev $300M-$310M

Actuant Corporation designs, manufactures, and distributes a range of industrial products and systems worldwide. The company has market cap of $1.52 billion. It operates through three divisions: Industrial, Energy, and Engineered Solutions. It currently has negative earnings. The Industrial segment is primarily involved in the design, manufacture, and distribution of branded hydraulic and mechanical tools to the maintenance, industrial, infrastructure, and production automation markets under the Enerpac, Simplex, Precision-Hayes, Milwaukee Cylinder, and Larzep brand names.

Since January 30, 2019, it had 0 buys, and 1 insider sale for $231,901 activity. Roundhouse Roger also sold $231,901 worth of Actuant Corporation (NYSE:ATU) shares.

Bristol-Myers Squibb Company (NYSE:BMY) Institutional Positions Chart